SpringWorks Therapeutics
100 Washington Blvd
Stamford
Connecticut
06902
United States
Website: http://www.springworkstx.com/
Email: Media@springworkstx.com
135 articles with SpringWorks Therapeutics
-
SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors
3/8/2023
SpringWorks Therapeutics, Inc. announced today that data from the Phase 3 DeFi trial of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors, were published in the New England Journal of Medicine (NEJM).
-
SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
3/1/2023
SpringWorks Therapeutics, Inc. today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 12:50 p.m. ET.
-
SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
2/28/2023
SpringWorks Therapeutics, Inc. reported financial results for the fourth quarter and full-year periods ended December 31, 2022 and provided an update on recent company developments.
-
SpringWorks Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Nirogacestat for the Treatment of Adults with Desmoid Tumors– PDUFA Action Date Set for August 27, 2023
2/27/2023
SpringWorks Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for nirogacestat.
-
SpringWorks Therapeutics Highlights 2022 Accomplishments and Anticipated Milestones for 2023 at the 41st Annual J.P. Morgan Healthcare Conference
1/9/2023
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, will present at the 41st Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT, and a live webcast will be available at ir.springworkstx.com.
-
SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
SpringWorks Therapeutics, Inc. announced that Saqib Islam, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 7:30 a.m. PT.
-
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors
12/27/2022
SpringWorks Therapeutics, Inc. announced that the Company has completed the submission of a New Drug Application to the United States Food and Drug Administration for nirogacestat, an investigational gamma secretase inhibitor, for the treatment of adults with desmoid tumors.
-
SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference
11/22/2022
SpringWorks Therapeutics, Inc. today announced that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference, taking place virtually on Tuesday, November 29, 2022 at 4:20 p.m. ET.
-
SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
11/3/2022
SpringWorks Therapeutics, Inc. reported third quarter financial results for the period ended September 30, 2022 and provided an update on recent company developments.
-
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
9/29/2022
SpringWorks Therapeutics, Inc. announced that the first patient has been dosed in a Phase 2 trial evaluating nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, as a monotherapy in patients with recurrent ovarian granulosa cell tumors.
-
SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022
9/10/2022
SpringWorks Therapeutics, Inc. announced that data from the Phase 3 DeFi trial of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors, are being presented as a late-breaking oral presentation during a Presidential Symposium at the European Society for Medical Oncology Congress 2022.
-
SpringWorks, Eli Lilly, EMD Serono and Mirati released data ahead of the European Society of Medical Oncology (ESMO) 2022 Meeting in Paris.
-
SpringWorks announced the expansion of its partnership with GlaxoSmithKline to develop nirogacestat in combination with GSK's Blenrep for relapsed or refractory multiple myeloma.
-
SpringWorks Therapeutics Announces $225 Million Private Placement Financing
9/7/2022
SpringWorks Therapeutics, Inc. announced that it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 8,625,520 shares of its common stock at a price per share of $26.01 in a private placement transaction.
-
SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma
9/7/2022
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), today announced that it has entered into an expanded global, non-exclusive license and collaboration agreement with GSK plc (LSE/NYSE: GSK) for nirogacestat, SpringWorks’ investigational oral gamma secretase inhibitor, in combination with Blenrep (belantamab mafodotin-blmf), GSK’s antibody-drug conjugate targeting B-cell maturation antigen (BCMA).
-
SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022
8/19/2022
SpringWorks Therapeutics, Inc. announced that data from the Phase 3 DeFi trial of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors, will be presented as a late-breaking oral presentation at the European Society for Medical Oncology Congress 2022.
-
SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
8/4/2022
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, reported second quarter financial results for the period ended June 30, 2022 and provided an update on recent company developments.
-
SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference
8/2/2022
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on Wednesday, August 10th at 10:55 a.m. ET.
-
SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors
7/15/2022
SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced the appointment of Carlos Albán to the Company’s Board of Directors.
-
SpringWorks Therapeutics to Present Progress Across the Company’s Targeted Oncology Portfolio at Virtual R&D Day
6/10/2022
SpringWorks Therapeutics, Inc., announced that the Company will host a virtual R&D Day , Friday, June 10th from 10:00 a.m. to 1:00 p.m. ET.